



Medicine: budesonide (brand name: Jorveza®)

Dr Falk Pharma UK Ltd

The Scottish Medicines Consortium (SMC) has assessed budesonide for the treatment of adults with eosinophilic oesophagitis. This document summarises the SMC decision and what it means for patients.

What has SMC said?

After careful consideration, SMC has accepted budesonide for use in certain patients (restricted use).

The restriction means that budesonide may be used to treat patients with eosinophilic oesophagitis, where patients have not been successfully treated with a type of medicine called a proton pump inhibitor.

What does SMC's decision mean for patients?

If your healthcare professional thinks that budesonide for use as described above is the right medicine for you, you should be able to have the treatment on the NHS in Scotland.



What is budesonide used for?

Budesonide is used to treat adults with a rare condition called eosinophilic oesophagitis. It causes inflammation of the passage that leads from the mouth to the stomach (oesophagus). This causes difficulties in swallowing food. It is caused by a build-up of a type of white blood cell called eosinophils in the lining of the oesophagus.

How does budesonide work?

Budesonide is a type of medicine called a corticosteroid. It works by reducing the release of substances that cause inflammation. By doing this it can reduce the inflammation in the oesophagus and relieve the symptoms of eosinophilic oesophagitis.

How does SMC make its decision?

SMC carefully considers every new medicine to make sure it benefits patients and is considered to be an acceptable use of the limited resources in NHSScotland.

To do this SMC considers the following:

- Evidence from the company about how well the medicine works compared with current treatments available in Scotland, in relation to how much they will cost to buy and administer.
- The potential impact of the medicine on patients and carers.
- Advice from healthcare professionals about any benefits of the new medicine compared to current treatment, along with how the new medicine is likely to be used.

When SMC assesses a medicine it takes account of the needs of all patients in NHSScotland, not just those who may be treated with the medicine under consideration.

You can find more detailed information about the SMC assessment of budesonide by looking at the SMC Detailed Advice Document (SMC2158).

More information

The organisations below can provide more information and support for people with eosinophilic oesophagitis and their families. SMC is not responsible for the content of any information provided by external organisations.

EOS Network



<https://www.eosnetwork.org>



0333 772 1309

Guts UK Charity



<https://gutscharity.org.uk>



0207 486 0341

You can find out more about budesonide (Jorveza®) in the European public assessment report (EPAR) summary for the public by searching for the medicine name on the European Medicines Agency (EMA) website.



<http://www.ema.europa.eu>